The FDA has issued a Complete Response Letter (CRL) to Acadia Pharmaceuticals Inc (NASDAQ:ACAD) regarding its supplemental marketing application for pimavanserin in…
Collaboration expands to include development of monospecific antibody candidates to address malignant solid tumors
Expanded collaboration leverages Genmab's proprietary HexaBody® technology platform to
As Russia's invasion of Ukraine continues for the fifth month, Tesla Inc (NASDAQ: TSLA) CEO Elon Musk once again touted the possibility of taking on President Vladimir Putin in single combat.
The mudslinging seems to go on endlessly in the Twitter, Inc. (NYSE: TWTR)-Elon Musk saga. The latest episode has seen the social media platform filing a 127-page response to the Tesla, Inc.
Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund.